CDK6 and sarcoma: The availability of CDK4 and CDK6 cyclin inhibitor drugs (anti-CDK4 and anti-CDK6) makes them excellent choices for targeting sarcomas with these genetic alterations in the form of deletions or amplifications [121,122].